EP Patent

EP4406950A3 — Lfa-1 inhibitor and polymorph thereof

Assigned to Bausch and Lomb Ireland Ltd · Expires 2025-04-23 · 1y expired

What this patent protects

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.

USPTO Abstract

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP4406950A3
Jurisdiction
EP
Classification
—
Expires
2025-04-23
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.